Literature DB >> 30059973

SCN5A mutations in 442 neonates and children: genotype-phenotype correlation and identification of higher-risk subgroups.

Alban-Elouen Baruteau1,2,3,4, Florence Kyndt4, Elijah R Behr1, Arja S Vink5,6, Matthias Lachaud4, Anna Joong7, Jean-Jacques Schott4, Minoru Horie8, Isabelle Denjoy9, Lia Crotti10, Wataru Shimizu11,12, Johan M Bos13,14,15, Elizabeth A Stephenson16, Leonie Wong1, Dominic J Abrams17, Andrew M Davis18,19, Annika Winbo1,2,20, Anne M Dubin21, Shubhayan Sanatani22, Leonardo Liberman7, Juan Pablo Kaski23,24, Boris Rudic25,26, Sit Yee Kwok27, Claudine Rieubland28, Jacob Tfelt-Hansen29,30, George F Van Hare31, Béatrice Guyomarc'h-Delasalle4, Nico A Blom5, Yanushi D Wijeyeratne1, Jean-Baptiste Gourraud4, Hervé Le Marec4, Junichi Ozawa8, Véronique Fressart32, Jean-Marc Lupoglazoff33, Federica Dagradi10, Carla Spazzolini10, Takeshi Aiba11, David J Tester13,14,15, Laura A Zahavich16, Virginie Beauséjour-Ladouceur17, Mangesh Jadhav18, Jonathan R Skinner20,34, Sonia Franciosi22, Andrew D Krahn22, Mena Abdelsayed35, Peter C Ruben35, Tak-Cheung Yung27, Michael J Ackerman13,14,15, Arthur A Wilde6,36, Peter J Schwartz10, Vincent Probst4.   

Abstract

Aims: To clarify the clinical characteristics and outcomes of children with SCN5A-mediated disease and to improve their risk stratification. Methods and results: A multicentre, international, retrospective cohort study was conducted in 25 tertiary hospitals in 13 countries between 1990 and 2015. All patients ≤16 years of age diagnosed with a genetically confirmed SCN5A mutation were included in the analysis. There was no restriction made based on their clinical diagnosis. A total of 442 children {55.7% boys, 40.3% probands, median age: 8.0 [interquartile range (IQR) 9.5] years} from 350 families were included; 67.9% were asymptomatic at diagnosis. Four main phenotypes were identified: isolated progressive cardiac conduction disorders (25.6%), overlap phenotype (15.6%), isolated long QT syndrome type 3 (10.6%), and isolated Brugada syndrome type 1 (1.8%); 44.3% had a negative electrocardiogram phenotype. During a median follow-up of 5.9 (IQR 5.9) years, 272 cardiac events (CEs) occurred in 139 (31.5%) patients. Patients whose mutation localized in the C-terminus had a lower risk. Compound genotype, both gain- and loss-of-function SCN5A mutation, age ≤1 year at diagnosis in probands and age ≤1 year at diagnosis in non-probands were independent predictors of CE.
Conclusion: In this large paediatric cohort of SCN5A mutation-positive subjects, cardiac conduction disorders were the most prevalent phenotype; CEs occurred in about one-third of genotype-positive children, and several independent risk factors were identified, including age ≤1 year at diagnosis, compound mutation, and mutation with both gain- and loss-of-function.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30059973     DOI: 10.1093/eurheartj/ehy412

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  7 in total

Review 1.  Practical Aspects in Genetic Testing for Cardiomyopathies and Channelopathies.

Authors:  Han-Chih Hencher Lee; Chor-Kwan Ching
Journal:  Clin Biochem Rev       Date:  2019-11

2.  Managing Patients With Advanced Atrioventricular Block: The Essential Role of Cardiovascular Magnetic Resonance Imaging for Timely and Accurate Diagnosis.

Authors:  Lisa von Wald; Chetan Shenoy
Journal:  J Am Heart Assoc       Date:  2022-06-06       Impact factor: 6.106

3.  Identification of Novel SCN5A Single Nucleotide Variants in Brugada Syndrome: A Territory-Wide Study From Hong Kong.

Authors:  Gary Tse; Sharen Lee; Tong Liu; Ho Chuen Yuen; Ian Chi Kei Wong; Chloe Mak; Ngai Shing Mok; Wing Tak Wong
Journal:  Front Physiol       Date:  2020-09-18       Impact factor: 4.566

4.  SCN5A Mutation Type and a Genetic Risk Score Associate Variably With Brugada Syndrome Phenotype in SCN5A Families.

Authors:  Yanushi D Wijeyeratne; Michael W Tanck; Yuka Mizusawa; Velislav Batchvarov; Julien Barc; Lia Crotti; J Martijn Bos; David J Tester; Alison Muir; Christian Veltmann; Seiko Ohno; Stephen P Page; Joseph Galvin; Rafik Tadros; Martina Muggenthaler; Hariharan Raju; Isabelle Denjoy; Jean-Jacques Schott; Jean-Baptiste Gourraud; Doris Skoric-Milosavljevic; Eline A Nannenberg; Richard Redon; Michael Papadakis; Florence Kyndt; Federica Dagradi; Silvia Castelletti; Margherita Torchio; Thomas Meitinger; Peter Lichtner; Taisuke Ishikawa; Arthur A M Wilde; Kazuhiro Takahashi; Sanjay Sharma; Dan M Roden; Martin M Borggrefe; Pascal P McKeown; Wataru Shimizu; Minoru Horie; Naomasa Makita; Takeshi Aiba; Michael J Ackerman; Peter J Schwartz; Vincent Probst; Connie R Bezzina; Elijah R Behr
Journal:  Circ Genom Precis Med       Date:  2020-11-09

5.  ARumenamides: A novel class of potential antiarrhythmic compounds.

Authors:  Mena Abdelsayed; Dana Page; Peter C Ruben
Journal:  Front Pharmacol       Date:  2022-09-28       Impact factor: 5.988

6.  Clinical Spectrum of SCN5A Channelopathy in Children with Primary Electrical Disease and Structurally Normal Hearts.

Authors:  Teresa Villarreal-Molina; Gabriela Paola García-Ordóñez; Álvaro E Reyes-Quintero; Mayra Domínguez-Pérez; Leonor Jacobo-Albavera; Santiago Nava; Alessandra Carnevale; Argelia Medeiros-Domingo; Pedro Iturralde
Journal:  Genes (Basel)       Date:  2021-12-22       Impact factor: 4.096

7.  Cardiac phenotype in ATP1A3-related syndromes: A multicenter cohort study.

Authors:  Simona Balestrini; Mohamad A Mikati; Reyes Álvarez-García-Rovés; Michael Carboni; Arsen S Hunanyan; Bassil Kherallah; Melissa McLean; Lyndsey Prange; Elisa De Grandis; Alessandra Gagliardi; Livia Pisciotta; Michela Stagnaro; Edvige Veneselli; Jaume Campistol; Carmen Fons; Leticia Pias-Peleteiro; Allison Brashear; Charlotte Miller; Raquel Samões; Vesna Brankovic; Quasar S Padiath; Ana Potic; Jacek Pilch; Aikaterini Vezyroglou; Ann M E Bye; Andrew M Davis; Monique M Ryan; Christopher Semsarian; Georgina Hollingsworth; Ingrid E Scheffer; Tiziana Granata; Nardo Nardocci; Francesca Ragona; Alexis Arzimanoglou; Eleni Panagiotakaki; Inês Carrilho; Claudio Zucca; Jan Novy; Karolina Dzieżyc; Marek Parowicz; Maria Mazurkiewicz-Bełdzińska; Sarah Weckhuysen; Roser Pons; Sergiu Groppa; Daniel S Sinden; Geoffrey S Pitt; Andrew Tinker; Michael Ashworth; Zuzanna Michalak; Maria Thom; J Helen Cross; Rosaria Vavassori; Juan P Kaski; Sanjay M Sisodiya
Journal:  Neurology       Date:  2020-09-10       Impact factor: 11.800

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.